We are live on ! Find out more
PHAR

Pharming Group
PHAR

3 hedge funds and large institutions have $180K invested in Pharming Group in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

2% less capital invested

Capital invested by funds: $184K → $180K (-$4K)

25% less funds holding

Funds holding: 4 → 3 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
3
Holders Change
-1
Holders Change %
-25%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CPA
Cowen Prime Advisors
New York
+$5.32K
2
UBS Group
UBS Group
Switzerland
+$1.72K

Top Sellers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
-$9K
Name Holding Trade Value Shares
Change 		Change in
Stake
CPA
1
Cowen Prime Advisors
New York
$145K +$5.32K +650 +4%
Morgan Stanley
2
Morgan Stanley
New York
$22K – – –
UBS Group
3
UBS Group
Switzerland
$13K +$1.72K +210 +17%
Wells Fargo
4
Wells Fargo
California
– -$9K -974 Closed

PHAR Hedge Fund Activity: Q2 2022 in Review

3 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Pharming Group (PHAR) for Q2 2022, worth a combined $180K — down 2.2% from $184K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of PHAR and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 2 added.

The largest buyer was Cowen Prime Advisors, adding an estimated $5.32K. The largest seller was Wells Fargo, exiting entirely with an estimated $9K sold.

  • 3 institutional investors held Pharming Group (PHAR) as of Q2 2022, down from 4 in Q1 2022.
  • Funds reported $180K of Pharming Group stock for Q2 2022, down 2.2% quarter-over-quarter.
  • 0 funds opened new Pharming Group positions in Q2 2022 and 1 closed out, a net change of -1 holder.
  • The largest Pharming Group buyer in Q2 2022 was Cowen Prime Advisors, an estimated $5.32K added.
  • The largest Pharming Group seller in Q2 2022 was Wells Fargo, an estimated $9K sold.

Based on aggregated 13F filings for Q2 2022.